3. Silver Lining for Biotechnology ETFs After Pfizer Calls off Allergan Deal
Pfizer (NasdaqGS: PFE) called off the deal with Allergan (NasdaqGS: AGN) on Wednesday, but there was a silver lining. Exchange traded funds that track the biotechnology sector surged as traders speculated that the two companies could court other merger targets. Read more >>
4. ETF Strategies for an Earnings Recession
We have seen and heard a lot of discussion about the current “earnings recession” and it sounds like really bad news for the stock market. Depending on which measurement of S&P 500 earnings per share (EPS) is utilized, comparisons have been negative for the past two to four quarters as Q4 2015 EPS will finish around -3.6% year over year. This meets the common “recession” definition of two or more quarters of negative growth. Read more >>
5. Why This Dividend ETF Continues to Work
With the Federal Reserve standing pat on interest rate increases to this point in 2016, high dividend stocks and the related exchange traded funds have benefited in significant fashion. However, that does not change the fact that high yielders are vulnerable to higher interest rates. Read more >>